Policy & Regulation
Oragenics Inc to issue common stock in public offering
20 November 2020 -

Oragenics Inc (NYSE American:OGEN), a company focused on the creation of a vaccine candidate to combat COVID-19, announced on Thursday the launch of a proposed underwritten public offering of common stock.

The company plans to provide the underwriter of the offering with a 45-day option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.

AGP/Alliance Global Partners is acting as sole book-running manager for the offering.

The offering is subject to market and other conditions, and Oragenics said that there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The company intends to use the net proceeds of the offering primarily to continue funding pre-clinical development of its SARS-CoV-2 vaccine, Terra CoV-2, and its lantibiotics program as well as for general corporate purposes, including research and development activities, capital expenditures and working capital.